Skip to content

Released Mar 19, 2026, after the close

10-K filed Mar 19, 2026, 78 days after period end · 0001390478-26-000003

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$7.66MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$8,255,000N/M
Operating Cash Flowderived-$4,921,000N/M

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue——$0.00$0.00
Net Income-$7.66M-$6.74M-$8.14M-$9.12M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR